US Stock Market Move | Lilly (LLY.US) rose nearly 4% today, and Foundayo's weight loss effects are significant.

On Monday, Eli Lilly (LLY.US) rose nearly 4%, closing at $1175.92. In terms of news, on June 7th, Lilly announced at the American Diabetes Association's annual scientific meeting the latest analysis data of its experimental weight loss drug Foundayo, showing that overweight or obese women in the ATTAIN-1 trial who received the highest dose experienced a weight loss of 12.8% to 14.4% within 72 weeks. The weight loss effect was not affected by menopausal transition status, potentially expanding the potential market for its obesity product line.